RecruitingPhase 3NCT06456346
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Bomedemstat(drug)
- Enrollment
- 300 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Palo Verde Cancer Specialists ( Site 0052), Glendale, Arizona, United States
- Los Angeles Cancer Network ( Site 0025), Glendale, California, United States
- Stanford Cancer Center ( Site 0024), Palo Alto, California, United States
- Exempla Lutheran Medical Center ( Site 0014), Golden, Colorado, United States
- Yale University School of Medicine ( Site 0051), New Haven, Connecticut, United States
- Parkview Research Center at Parkview Regional Medical Center ( Site 0006), Fort Wayne, Indiana, United States
- University of Michigan ( Site 0003), Ann Arbor, Michigan, United States
- Optum Care Cancer Center ( Site 0053), Las Vegas, Nevada, United States
- Levine Cancer Institute ( Site 0009), Charlotte, North Carolina, United States
- Duke University Health System (DUHS) ( Site 0012), Durham, North Carolina, United States
- Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013), Winston-Salem, North Carolina, United States
- The Ohio State University Wexner Medical Center ( Site 0028), Columbus, Ohio, United States
- Oregon Health & Science University ( Site 0018), Portland, Oregon, United States
- University of Texas MD Anderson Cancer Center ( Site 0026), Houston, Texas, United States
- University of Texas Health Science Center at San Antonio ( Site 0021), San Antonio, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06456346 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.